Profound is commercializing TULSA-PRO, a technology that combines real-time MRI, AI-enhanced planning, robotically-driven transurethral ultrasound and closed-loop temperature feedback control with potential to become a mainstream treatment modality across the entire prostate disease spectrum. The company recently regained exclusive distribution rights for TULSA-PRO in Canada.
Cyborg Score Rationale
In 2024, Profound Medical's revenue was $10.68 million, an increase of 48.35% compared to the previous year. However, the company faces significant losses and remains in early commercial stage. Recent litigation against the company and early-stage commercialization challenges offset strong technology platform and revenue growth.
Top Insights
Strong revenue growth of 48% YoY in 2024, reaching $10.68M, demonstrates early market traction
Recently recovered Canadian distribution rights for TULSA-PRO from Knight Therapeutics as of November 2025, enabling direct market expansion
Platform targets large TAM across prostate cancer, BPH, uterine fibroids and other tissue ablation applications
Company operates with significant operating losses ($27.82M in 2024) as typical for early-stage commercial medical device companies
Named Competitors
HIFU/Focused Ultrasound Systems — Competing ultrasound-based thermal ablation platforms
Transurethral Resection — Traditional surgical alternatives for prostate treatment
MRI-Guided Thermal Ablation — Other MRI-guided therapeutic platforms
Recent Developments
(Nov 2025) Regained exclusive distribution rights for TULSA-PRO in Canada from Knight Therapeutics
(2024) Revenue grew 48% YoY to $10.68M; company initiated direct sales efforts in North America
(2025) Multiple lawsuits filed against company by institutional investors regarding business practices
Open the full interactive Profound Medical Corp. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.